文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性中模拟抗VEGF转换:HARBOR亚组分析

Simulating an Anti-Vascular Endothelial Growth Factor Switch in Neovascular Age-Related Macular Degeneration: A HARBOR Subanalysis.
PubMed 文献 · Ophthalmology · 2019-01-11

该研究为HARBOR试验的事后分析,在3或6个月时按预定标准识别出应答不佳的转换候选者,但未实际转换而继续雷珠单抗治疗。结果显示仅4.2%和4.8%患者符合标准,继续治疗后视力和解剖结构仍改善。

要点

  • 3个月和6个月时分别仅4.2%和4.8%患者符合模拟转换标准。
  • 符合标准者继续雷珠单抗治疗,24个月内视力仍有提升。
  • 两组患者24个月内中心凹厚度均显著降低。

核心结论

  • 符合模拟转换标准的患者继续原雷珠单抗治疗仍可获得视力与解剖获益。

研究设计与样本

  • HARBOR三期临床试验的事后分析,纳入1059例(3个月分析)和769例(6个月分析)新生血管性AMD患者。

主要发现

  • 3个月转换候选者从3到12个月平均 gain 5.3个字母,从3到24个月 gain 2.7个字母。
  • 6个月转换候选者从6到12个月平均 gain 1.6个字母,从6到24个月 gain 1.8个字母。
  • 两组患者24个月内中心凹厚度均显著降低。

关键数值与推荐

  • 转换标准:基线以来视力增益≤5个字母、BCVA≤20/40、存在视网膜内或视网膜下液且CFT≥中心子区域厚度。

临床怎么用

  • 对于短期应答不佳但符合转换标准的患者,继续原抗VEGF治疗仍可能获得改善,转换决策需谨慎。

局限性

  • 为事后分析,模拟转换非真实转换,结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A simulated switching study assessed the effects of continuing the same anti-vascular endothelial growth factor (VEGF) treatment among patients who typically are considered for a therapy switch. Post hoc analysis of data from HARBOR was undertaken. Patients with neovascular age-related macular degeneration who demonstrated a suboptimal response after 3 or 6 months of ranibizumab treatment were identified as switching candidates. Rather than switching, however, patients continued on ranibizumab treatment, and visual and anatomic outcomes from the point of the hypothetical switch were examined. DESIGN: Post hoc analysis of the phase 3 HARBOR clinical trial. PARTICIPANTS: Patients were included in 3- and 6-month switcher analyses if they received 3 of 3 initial monthly ranibizumab doses and 5 of 6 initial monthly ranibizumab doses, respectively, and met all the following: 5-letter or fewer gain from baseline, best-corrected visual acuity (BCVA) 20/40 or worse, and intraretinal or subretinal fluid with central foveal thickness (CFT) equal to or greater than central subfield thickness. METHODS: Patient data were examined at months 3 and 6 to identify those who met predetermined switching criteria. Best-corrected visual acuity and CFT were examined from the point at which switching criteria were met through months 6, 12, 18, and 24 of HARBOR and compared with those who did not meet the criteria. MAIN OUTCOME MEASURES: Outcome measures included mean BCVA and CFT change over time from the point (month 3 or 6) at which switching criteria were met. RESULTS: By months 3 and 6, only 44 of 1059 patients (4.2%) and 37 of 769 patients (4.8%), respectively, met the inclusion criteria for hypothetical switching. Patients who met switching criteria at month 3 gained, on average, 5.3 letters from months 3 to 12 and 2.7 letters from months 3 to 24. Month 6 switchers gained, on average, 1.6 letters from months 6 to 12 and 1.8 letters from months 6 to 24. Both groups experienced significant CFT reductions over 24 months. CONCLUSIONS: Month 3 hypothetical switchers achieved vision and anatomic improvement while continuing their original ranibizumab treatment. Month 6 switcher outcomes replicated those commonly reported in published anti-VEGF switching studies: stable vision or nominal improvements in vision with continued substantial anatomic improvement.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Zarbin M, Tsuboi M, Hill LF, et al. Simulating an Anti-Vascular Endothelial Growth Factor Switch in Neovascular Age-Related Macular Degeneration: A HARBOR Subanalysis. Ophthalmology. 2019. PMID: 30641096. doi:10.1016/j.ophtha.2019.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。